Investment analysts at Lifesci Capital decreased their FY2025 earnings per share (EPS) estimates for Olema Pharmaceuticals in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback